Head and neck cancer - cetuximab: final appraisal determination (30th April 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Cetuximab for the treatment of head and neck cancer and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 15th May 2008.
Click here for the Final Appraisal Determination
Click here for Response to consultee, commentator and public comments on the ACD and comments from website consultation
Click here for Consultee and commentator comments on the ACD
Click here for Expert comments on the ACD
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Cetuximab for the treatment of head and neck cancer and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 15th May 2008.
Click here for the Final Appraisal Determination
Click here for Response to consultee, commentator and public comments on the ACD and comments from website consultation
Click here for Consultee and commentator comments on the ACD
Click here for Expert comments on the ACD
No comments:
Post a Comment